Biologicals Archives - Page 34 of 54

Abstract Number: 2145 • ACR Convergence 2022
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials
Lars Erik¹, Kim Papp², Douglas White³, Cecilia Asnal⁴, Wenjing Lu⁵, Ahmed Soliman⁵, Byron Padilla⁶, Michael Chen⁵ and Andrew Ostor⁷, ¹Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ²K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ³Rheumatology Department, Waikato Hospital, and Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ⁴Hospital Alemán, Buenos Aires, Argentina, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Waukegan, IL, ⁷Cabrini Hospital, Monash University & Emeritus Research, Melbourne, Australia
Background/Purpose: PsA is a chronic, systemic inflammatory disease with a variety of clinical manifestations including arthritis, enthesitis, and dactylitis and is associated with skin and…
Abstract Number: 0290 • ACR Convergence 2022
Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)
Kim Lauper¹, Romain Aymon², Denis Mongin², Sytske Anne Bergstra³, Denis Choquette⁴, Catalin Codreanu⁵, Ori Elkayam⁶, Kimme Hyrich⁷, Florenzo Iannone⁸, Nevsun Inanc⁹, Lianne Kearsley-Fleet¹⁰, Tore K. kvien¹¹, Eirik Kristianslund¹², Burkhard Leeb¹³, Galina Lukina¹⁴, Dan Nordstrom¹⁵, Karel Pavelka¹⁶, Manuel Pombo-Suarez¹⁷, Ziga Rotar¹⁸, Maria José Santos¹⁹, Delphine Courvoisier²⁰ and Axel Finckh²¹, ¹Geneva University Hospitals, Genéve, Switzerland, ²Geneva University Hospitals, Geneva, Switzerland, ³LUMC, Leiden, Netherlands, ⁴Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁵Center for Rheumatic Diseases, Bucharest, Romania, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷The University of Manchester, Manchester, United Kingdom, ⁸School of Medicine University of Bari, Bari, Italy, ⁹Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, ¹⁰Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, ¹¹Diakonhjemmet Hospital, Oslo, Norway, ¹²Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway, ¹³Bioreg, Stockerau, Austria, ¹⁴Federal state budgetary scientific institution �Research Institute of rheumatology named after V. A. Nasonova�, Moscow, Russia, ¹⁵Helsinki University Hospital, Helsinki, Finland, ¹⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ¹⁷Hospital Clinico Universitario, Santiago de Compostela, Spain, ¹⁸University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁹Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, ²⁰University Hospitals of Geneva, Geneva, Switzerland, ²¹Geneva University Hospital, Geneve - Vesenaz, Switzerland

Background/Purpose: The "ORAL Surveillance" study1 suggests an increased risk of serious adverse events (AEs) with tofacitinib, a JAK-inhibitor (JAKi), compared to TNF-inhibitors (TNFi). Currently, there…
Abstract Number: 0367 • ACR Convergence 2022
Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use
April Jorge¹, Baijun Zhou¹, yuqing zhang² and Hyon Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Patients with SLE are at increased risk of COVID-19 and its severe outcomes, in part due to the use of immunosuppressants. We sought to…
Abstract Number: 0512 • ACR Convergence 2022
Development of CARRA Biologic Consensus Treatment Plans for Management of Refractory Moderate Juvenile Dermatomyositis
Matthew Sherman¹, Hanna Kim² and Stacey Tarvin³, ¹Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH); Children’s National Hospital, Washington, DC, ²Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ³Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: There is a paucity of prospective clinical trials evaluating treatments for juvenile dermatomyositis (JDM). Consensus treatment plans (CTPs) are designed to facilitate comparative effectiveness…
Abstract Number: 0785 • ACR Convergence 2022
Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study
Hilde Ørbo¹, Kristin Hammersbøen Bjørlykke², Joe Sexton¹, Anne Therese Tveter¹, Ingrid Jyssum¹, Ingrid Egeland Christensen¹, David Warren³, Tore K. Kvien¹, Adity Chopra⁴, Grete Birkeland Kro³, Jørgen Jahnsen², Ludvig A. Munthe³, Espen Haavardsholm¹, Gunnveig Grødeland³, Sella Aarrestad Provan¹, Kristin Kaasen Jørgensen², Silje Watterdal Syversen¹ and Guro Løvik Goll¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Oslo, Norway
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy have impaired humoral immune responses to SARS-CoV-2 vaccination. This study aimed to assess serologic response…
Abstract Number: 0917 • ACR Convergence 2022
Fifty-two-week Results from a Phase 3, Randomized, Double-blind, Active-controlled Clinical Trial to Compare BAT1806/BIIB800, a Proposed Tocilizumab Biosimilar, with a Tocilizumab Reference Product in Subjects with Moderate to Severe RA with an Inadequate Response to Methotrexate
Xiaomei Leng¹, Piotr Leszczynski², Sławomir Jeka³, Shengyun Liu⁴, Huaxiang Liu⁵, Malgorzata Miakisz⁶, Jieruo Gu⁷, Lali Kilasonia⁸, Mykola Stanislavchuk⁹, Xiaolei Yang¹⁰, Yinbo Zhou¹¹, Qingfeng Dong¹¹, Marian Mitroiu¹², Janet Addison¹³ and Xiaofeng Zeng¹⁴, ¹Peking Union Medical College Hospital, Department of Rheumatology and Clinical Immunology, Beijing, China, ²Poznan University of Medical Sciences, Department of Rheumatology, Rehabilitation and Internal Medicine, Poznan, Poland, ³University Hospital No 2 in Bydgoszcz Collegium Medicum UMK, Clinic and Department of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁴First Affiliated Hospital of Zhengzhou University, Department of Rheumatology and Immunology, Zhengzhou, China, ⁵Qilu Hospital of Shandong University, Department of Rheumatology, Jinan, China, ⁶Twoja Przychodnia Centrum Medyczne, Internal Medicine and Rheumatology, Nowa Sól, Poland, ⁷The Third Affiliated Hospital of Sun Yat-sen University, Department of Rheumatology, Guangzhou, China, ⁸Tbilisi Heart and Vascular Clinic Ltd, Rheumatology, Tbilisi, Georgia, ⁹National Pirogov Memorial Medical University, Internal Medicine, Vinnytsia, Ukraine, ¹⁰Bio-Thera Solutions, Ltd., Research and Development, Guangzhou, China, ¹¹Bio-Thera Solutions Ltd, Research and Development, Guangzhou, China, ¹²Biogen International GmbH, Evidence Generation Biosimilars, Baar, Switzerland, ¹³Biogen Idec Ltd, Maidenhead, United Kingdom, ¹⁴Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: BAT1806 (also referred to as BIIB800) is a proposed biosimilar to tocilizumab reference product (TCZ). Results of this Phase 3, randomized, double-blind, active-controlled trial…
Abstract Number: 1073 • ACR Convergence 2022
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
Soko Kawashima¹, Mitsumasa Kishimoto², Yoshinori Komagata³ and Shinya kaname⁴, ¹Kyorin University, Mitaka Tokyo, Japan, ²Kyorin University School of Medicine, Yokohama, Japan, ³Kyorin University School of Medicine, Tokyo, Japan, ⁴Kyorin University, Tokyo, Japan
Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…
Abstract Number: 1424 • ACR Convergence 2022
Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial
Joanna KEDRA¹, Lina El Houari¹, Florence Tubach¹, Benjamin granger¹ and Bruno Fautrel², ¹Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, PEPITES, F75013, Paris, France, Paris, France, ²Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
Abstract Number: 1629 • ACR Convergence 2022
AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases
Shawn Morales, Jennifer Cross and Robert Huizinga, Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada
Background/Purpose: AUR200 targets both B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are key mediators in the pathogenesis of B cell-mediated autoimmune…
Abstract Number: 2031 • ACR Convergence 2022
Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
Dong Xu¹, Shangzhu Zhang¹, Cibo Huang², Chenghui Huang³, Li Qin⁴, Xiaomei Li⁵, Meiqing Chen⁶, Xiumei Liu⁷, Yi Liu⁸, Zhijun Li⁹, Jiankang Hu¹⁰, Chunde Bao¹¹, wei Wei¹², Jing Tian¹³, Xinwang Duan¹⁴, Jianmin Fang¹⁵ and Xiaofeng Zeng¹⁶, ¹Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Beijing Hospital, Beijing, China, ³The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ⁴Huzhou Third Municipal Hospital, Huzhou, China, ⁵Anhui Provincial Hospital, Hefei, China, ⁶The First Affiliated Hospital of Xiamen University, Xiamen, China, ⁷The First Hospital of Shanxi Medical University, Taiyuan, China, ⁸West China Hospital of Sichuan University, Chengdu, China, ⁹The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁰Jiangxi Pingxiang People’s Hospital, Shanghai, China, ¹¹Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ¹²Tianjin Medical University General Hospital, Tianjin, China, ¹³Second Xiangya Hospital of Central South University, Changsha, China, ¹⁴The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹⁵Shanghai Tongji Hospital, Shanghai, China, ¹⁶Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: To evaluate the efficacy and safety of telitacicept in adult patients with primary Sjögren’s syndrome (pSS) in a phase II randomized double-blind placebo-controlled trial.Methods:…
Abstract Number: 2151 • ACR Convergence 2022
Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
Kurt de Vlam¹, Peter Taylor², Philip J Mease³, Paul Peloso⁴, Dieter Wetzel⁵, Nicolai Brun⁵, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowinska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Frank Behrens¹², ¹University Hospitals Leuven, Leuven, Belgium, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴ACELYRIN, Naples, FL, ⁵Affibody AB, Solna, Sweden, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany
Background/Purpose: PsA is a chronic, inflammatory disease with multiple manifestations, with arthritis and skin involvement. Other areas of inflammation include enthesitis, dactylitis and nail involvement.…
Abstract Number: 0076 • ACR Convergence 2022
Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database
Ko-Jen Li¹, Kuo-Cherh Huang², Chia-Cheng Lin³ and Chia-Li Chang², ¹National Taiwan University Hospital, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Chugai Pharma Taiwan Ltd., Taipei, Taiwan
Background/Purpose: There is a growing concern over the rise of polypharmacy, arguably one of the most pressing prescribing challenges. The option of biologic monotherapy is…
Abstract Number: 0291 • ACR Convergence 2022
Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients
Naga Prabu¹, velammal petchaippan², Gayathri anand³, Aswathi kumar¹ and Saranya Ramachandiran³, ¹SAKTHI RHEUMATOLOGY CENTRE PVT LTD, Coimbatore, India, ²PSG INSTTUTE OF MEDICAL SCIENCES AND RESEARCH, Coimbatore, India, ³sakthi rheumatology centre pvt l;td, Coimbatore, India
Background/Purpose: Tofacitinib(Tofa) an oral Janus kinase inhibitor(JAK) has shown good promise in the management of rheumatoid arthritis and psoriatic arthritis. While being increasingly used in…
Abstract Number: 0391 • ACR Convergence 2022
Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data
William Tillett¹, Alexander Egeberg², Enikö Sonkoly³, Patricia Gorecki⁴, Anna Tjärnlund⁵, Jozefien Buyze⁶, Sven Wegner⁷ and Dennis McGonagle⁸, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ³Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Janssen-Cilag Ltd, High Wycombe, United Kingdom, ⁵Janssen-Cilag AB, Solna, Sweden, ⁶Janssen Pharmaceutica NV, Beerse, Belgium, ⁷Janssen-Cilag GmbH, Neuss, Germany, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Nail psoriasis can be difficult to treat, affects ~50% of patients with psoriasis and can involve the nail matrix (pitting, leukonychia) and/or nail bed…
Abstract Number: 0542 • ACR Convergence 2022
ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update
Sofia Ramiro¹, Elena Nikiphorou², Alexandre Sepriano³, Augusta Ortolan⁴, Casper Webers⁵, Xenofon Baraliakos⁶, Robert Landewé⁷, Filip Van den bosch⁸, Boryana Boteva⁹, Ann Bremander¹⁰, Philippe Carron¹¹, Adrian Ciurea¹², floris van Gaalen¹, Pal Geher¹³, Lianne Gensler¹⁴, Josef Hermann¹⁵, Manouk de Hooge¹⁶, Marketa Husakova¹⁷, Uta Kiltz¹⁸, Clementina Lopez-Medina¹⁹, Pedro Machado²⁰, Helena Marzo-Ortega²¹, Anna Molto²², Victoria Navarro-Compán²³, Michael Nissen²⁴, Fernando Pimentel-Santos²⁵, Denis Poddubnyy²⁶, Fabian Proft²⁶, Martin Rudwaleit²⁷, Mark Telkman⁹, Sizheng Zhao²⁸, Nelly Ziade²⁹ and Désirée van der Heijde³⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center & King's College London, London, United Kingdom, ³Leiden University Medical Centre, Portela Loures, Portugal, ⁴University of Padova/Leiden University Medical Center, Padova, Italy, ⁵Maastricht University Medical Centre, Maastricht, Netherlands, ⁶Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁷Amsterdam University Medical Center, Meerssen, Netherlands, ⁸Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁹Patients with Arthritis and Rheumatism (PARE) working group, EULAR, Zürich, Switzerland, ¹⁰Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark, ¹¹Ghent University Hospital, Ghent, Belgium, ¹²University Hospital Zurich, Zürich, Switzerland, ¹³Semmelweis University, Budapest, Hungary, ¹⁴Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ¹⁵Medical University of Graz, Graz, Austria, ¹⁶Ghent University Hospital, Luxembourg, Luxembourg, ¹⁷Department of Rheumatology, First Faculty of Medicine, Charles University and Rheumatology Institute, Prague, Prague, Czech Republic, ¹⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ¹⁹Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ²⁰University College London, London, United Kingdom, ²¹Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ²²Rheumatology Department, Hôpital Cochin,Assistance Publique- Hôpitaux de Paris, Paris, France, ²³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²⁴Hopitaux Universitaires de Genève, Geneva, Switzerland, ²⁵NOVA Medical School; Universidade NOVA e Lisboa, Lisboa, Portugal, ²⁶Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ²⁸University of Manchester, Liverpool, United Kingdom, ²⁹Saint-Joseph University, Beirut, Lebanon, ³⁰Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands
Background/Purpose: Since the last update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) in 2016, substantial new evidence has become available on…

Abstracts tagged "Biologicals"

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials

Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)

Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use

Development of CARRA Biologic Consensus Treatment Plans for Management of Refractory Moderate Juvenile Dermatomyositis

Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study

Fifty-two-week Results from a Phase 3, Randomized, Double-blind, Active-controlled Clinical Trial to Compare BAT1806/BIIB800, a Proposed Tocilizumab Biosimilar, with a Tocilizumab Reference Product in Subjects with Moderate to Severe RA with an Inadequate Response to Methotrexate

Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan

Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial

AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases

Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial

Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial

Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database

Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients

Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data

ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update